Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07142707Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Role: lead

NCT06465108Phase 2Completed

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

Role: lead

NCT07029412Phase 2Recruiting

Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

Role: lead

NCT06496217Phase 1Completed

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

Role: lead

NCT06531941Phase 2Active Not Recruiting

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

Role: lead

NCT06036784Phase 1Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

Role: lead

NCT05158335Phase 1Completed

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects

Role: lead

All 7 trials loaded